DEFENCE RETAINS
CATO SMS TO ADVISE ON ITS
PHASE
I CLINICAL TRIAL ON ACCUTOXTM
FOR
BREAST CANCER
Vancouver, BC,
Canada, February 16th,
2022 -- InvestorsHub NewsWire Defence Therapeutics Inc.
("Defence"
or the "Company"),
(CSE:DTC, USOTC:DTCFF) a pre-clinical biotechnology
company developing various products for the immune-oncology space,
is pleased to announce the establishment of an agreement with Cato
SMS, to advise on the submission of its clinical application to
Health Canada in order to initiate a Phase I trial using
AccuTOXTM
against breast
cancer.
CATO SMS is a
consulting firm with more than 30 years of global experience to
guide clinical development of biopharma pipelines. With offices
across North America, Europe, and the Middle East, CATO SMS has
experience conducting trial designs in more than 25 countries.
Their specialists deliver innovative regulatory consulting
solutions to guide complex challenges with a proven center of
excellence in oncology.
"We are very pleased to work with Cato SMS on our
AccuTOXTM
program. This step is central to Defence as it ensures the
achievement of important milestones for our clinical program. Cato
SMS will be designing the clinical protocol, pre-CTA meeting
package, CTA Compilation and Submission as well as regulatory
affairs for our AccuTOXTM
Phase I trial" says Mr. Plouffe, the CEO of Defence.
The AccuTOXTM
program consists of using a lead variant of the
AccumTM
molecule to trigger cell death in cancer cells. When combined with
the immune-checkpoint inhibitor CTLA-4, this lead
AccumTM
triggered potent anti-tumoral response in several cancer models
including, T-cell lymphoma, melanoma, colon and breast cancer. As
such, Defence plans to use AccuTOXTM
in its Phase I to treat breast cancer patients in Q4 of
2022.
According to Fortune Business InsightsTM,
the Global Breast Cancer Therapeutics Market to exhibit 13.1% CAGR
and hit USD 55.27 Billion till 2027.
About
Defence:
Defence
Therapeutics is a publicly-traded biotechnology company working on
engineering the next generation vaccines and ADC products using its
proprietary platform. The
core of Defence Therapeutics platform is the ACCUMTM
technology,
which enables precision delivery of vaccine antigens or ADCs in
their intact form to target cells. As a result, increased efficacy
and potency can be reached against catastrophic illness such as
cancer and infectious diseases.
For further
information:
Sebastien Plouffe,
President, CEO and Director
P: (514)
947-2272
Splouffe@defencetherapeutics.com
www.defencetherapeutics.com
Cautionary
Statement Regarding "Forward-Looking" Information
This release includes
certain statements that may be deemed "forward-looking statements".
All statements in this release, other than statements of historical
facts, that address events or developments that the Company expects
to occur, are forward-looking statements. Forward-looking
statements are statements that are not historical facts and are
generally, but not always, identified by the words "expects",
"plans", "anticipates", "believes", "intends", "estimates",
"projects", "potential" and similar expressions, or that events or
conditions "will", "would", "may", "could" or "should" occur.
Although the Company believes the expectations expressed in such
forward-looking statements are based on reasonable assumptions,
such statements are not guarantees of future performance and actual
results may differ materially from those in the forward-looking
statements. Factors that could cause the actual results to differ
materially from those in forward-looking statements include
regulatory actions, market prices, and continued availability of
capital and financing, and general economic, market or business
conditions. Investors are cautioned that any such statements are
not guarantees of future performance and actual results or
developments may differ materially from those projected in the
forward-looking statements. Forward-looking statements are based on
the beliefs, estimates and opinions of the Company's management on
the date the statements are made. Except as required by applicable
securities laws, the Company undertakes no obligation to update
these forward-looking statements in the event that management's
beliefs, estimates or opinions, or other factors, should
change.
Neither the
CSE nor its market regulator, as that term is defined in the
policies of the CSE, accepts responsibility for the adequacy or
accuracy of this release.
